相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas
Rodrigo A. Toledo et al.
CLINICAL CANCER RESEARCH (2016)
A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
Eli M. Wallace et al.
CANCER RESEARCH (2016)
HIF2A gain-of-function mutations detected in duodenal gangliocytic paraganglioma
Zhengping Zhuang et al.
ENDOCRINE-RELATED CANCER (2016)
Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome
Roland Darr et al.
ENDOCRINE-RELATED CANCER (2016)
Pathways for Oxygen Regulation and Homeostasis The 2016 Albert Lasker Basic Medical Research Award
William G. Kaelin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Targeting renal cell carcinoma with a HIF-2 antagonist
Wenfang Chen et al.
NATURE (2016)
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
Hyejin Cho et al.
NATURE (2016)
Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster
Stephanie M. J. Fliedner et al.
NEOPLASIA (2016)
Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2
Thomas H. Scheuerrnann et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Structural integration in hypoxia-inducible factors
Dalei Wu et al.
NATURE (2015)
Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas
Luis Jaime Castro-Vega et al.
NATURE COMMUNICATIONS (2015)
Unsaturated fatty acids as high-affinity ligands of the C-terminal Per-ARNT-Sim domain from the Hypoxia-inducible factor 3α
Angela M. Fala et al.
SCIENTIFIC REPORTS (2015)
Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia
Chunzhang Yang et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2015)
Paraganglioma and phaeochromocytoma: from genetics to personalized medicine
Judith Favier et al.
NATURE REVIEWS ENDOCRINOLOGY (2015)
Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma
Jenny Welander et al.
ENDOCRINE-RELATED CANCER (2014)
Mosaicism in HIF2A-Related Polycythemia-Paraganglioma Syndrome
Alexandre Buffet et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Germline FH Mutations Presenting With Pheochromocytoma
Graeme R. Clark et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Rare Germline Mutations Identified by Targeted Next-Generation Sequencing of Susceptibility Genes in Pheochromocytoma and Paraganglioma
Jenny Welander et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Polycythemia and Paraganglioma With a Novel Somatic HIF2A Mutation in a Male
Hidemi Toyoda et al.
PEDIATRICS (2014)
Integrative Genetic Characterization and Phenotype Correlations in Pheochromocytoma and Paraganglioma Tumours
Joakim Crona et al.
PLOS ONE (2014)
Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity
Patricia L. M. Dahia
NATURE REVIEWS CANCER (2014)
Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas
Chunzhang Yang et al.
BLOOD (2013)
SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma
Eric Letouze et al.
CANCER CELL (2013)
In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas
Rodrigo A. Toledo et al.
ENDOCRINE-RELATED CANCER (2013)
Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis
Inaki Comino-Mendez et al.
HUMAN MOLECULAR GENETICS (2013)
First Report of Bilateral Pheochromocytoma in the Clinical Spectrum of HIF2A-Related Polycythemia-Paraganglioma Syndrome
David Taieb et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Development of Inhibitors of the PAS-B Domain of the HIF-2α Transcription Factor
Jamie L. Rogers et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma
Felipe R. Lorenzo et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2013)
Hypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction
Ivana Jochmanova et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Allosteric inhibition of hypoxia inducible factor-2 with small molecules
Thomas H. Scheuermann et al.
NATURE CHEMICAL BIOLOGY (2013)
Integrated molecular analysis of clear-cell renal cell carcinoma
Yusuke Sato et al.
NATURE GENETICS (2013)
Anti-angiogenesis therapy in cancer: Current challenges and future perspectives
Farbod Shojaei
CANCER LETTERS (2012)
HIF2AMutations in Paraganglioma with Polycythemia
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Somatic HIF2A Gain-of-Function Mutations in Paraganglioma with Polycythemia
Zhengping Zhuang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Identification of Cys255 in HIF-1α as a novel site for development of covalent inhibitors of HIF-1α/ARNT PasB domain protein-protein interaction
Rosa Cardoso et al.
PROTEIN SCIENCE (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
SDHA is a tumor suppressor gene causing paraganglioma
Nelly Burnichon et al.
HUMAN MOLECULAR GENETICS (2010)
SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma
Jean-Pierre Bayley et al.
LANCET ONCOLOGY (2010)
Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma
Anthony M. Joshua et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor
Thomas H. Scheuermann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis
Melanie J. Percy et al.
BLOOD (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Brief Report: PHD2 Mutation and Congenital Erythrocytosis with Paraganglioma
Charline Ladroue et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A gain-of-function mutation in the HIF2A gene in familial erythrocytosis
Melanie J. Percy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
HYPOXIA AND METABOLISM SERIES - TIMELINE The impact of O2 availability on human cancer
Jessica A. Bertout et al.
NATURE REVIEWS CANCER (2008)
The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer
William G. Kaelin
NATURE REVIEWS CANCER (2008)
Pseudohypoxic pathways in renal cell carcinoma
Gennady Bratslavsky et al.
CLINICAL CANCER RESEARCH (2007)
Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo
Erinn B. Rankin et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Opinion - Angiogenesis: an organizing principle for drug discovery?
Judah Folkman
NATURE REVIEWS DRUG DISCOVERY (2007)
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
RK Jain et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
A HIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas
PLM Dahia et al.
PLOS GENETICS (2005)
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase
MA Selak et al.
CANCER CELL (2005)
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
N Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
CG Willett et al.
NATURE MEDICINE (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Structural basis for PAS domain heterodimerization in the basic helix-loop-helix-PAS transcription factor hypoxia-inducible factor
PJA Erbel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Inhibition of HIF2 alpha is sufficient to suppress pVHL-defective tumor growth
K Kondo et al.
PLOS BIOLOGY (2003)
C-elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation
ACR Epstein et al.
CELL (2001)
Novel mutations and the emergence of a common mutation in the SDHD gene causing familial paraganglioma
JM Milunsky et al.
AMERICAN JOURNAL OF MEDICAL GENETICS (2001)
HIFα targeted for VHL-mediated destruction by proline hydroxylation:: Implications for O2 sensing
M Ivan et al.
SCIENCE (2001)
Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation
P Jaakkola et al.
SCIENCE (2001)
Germline SDHD mutation in familial phaeochromocytoma
D Astuti et al.
LANCET (2001)
Mutations in SDHC cause autosomal dominant paraganglioma, type 3
S Niemann et al.
NATURE GENETICS (2000)
Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma
BE Baysal et al.
SCIENCE (2000)
分享论文
